During the recent session, Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s traded shares were 0.82 million, with the beta value of the company hitting 0.55. At the last check today, the stock’s price was $7.75, reflecting an intraday loss of -0.50% or -$0.04. The 52-week high for the IOVA share is $18.33, that puts it down -136.52 from that peak though still a striking 9.03% gain since the share price plummeted to a 52-week low of $7.05. The company’s market capitalization is $2.36B, and the average intraday trading volume over the past 10 days was 7.71 million shares, and the average trade volume was 6.54 million shares over the past three months.
Iovance Biotherapeutics Inc (IOVA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.40. IOVA has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.26.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Iovance Biotherapeutics Inc (IOVA) registered a -0.50% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.50% in intraday trading to $7.75, hitting a weekly high. The stock’s 5-day price performance is 1.99%, and it has moved by -11.21% in 30 days. Based on these gigs, the overall price performance for the year is -1.88%. The short interest in Iovance Biotherapeutics Inc (NASDAQ:IOVA) is 59.33 million shares and it means that shorts have 8.82 day(s) to cover.
The consensus price target of analysts on Wall Street is $11.75, which implies an increase of 34.04% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $17 respectively. As a result, IOVA is trading at a discount of -119.35% off the target high and -29.03% off the low.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Statistics show that Iovance Biotherapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Iovance Biotherapeutics Inc (IOVA) shares have gone up 6.47% during the last six months, with a year-to-date growth rate more than the industry average at 34.92% against 16.80. In the rating firms’ projections, revenue will increase 13,525.93% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 71.57M as predicted by 13 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 88.59M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 482k and 715k respectively. In this case, analysts expect current quarter sales to grow by 14,748.60% and then jump by 12,289.93% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -8.25%. While earnings are projected to return 33.29% in 2025.
IOVA Dividends
Iovance Biotherapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Iovance Biotherapeutics Inc insiders own 0.58% of total outstanding shares while institutional holders control 88.33%, with the float percentage being 88.85%. VANGUARD GROUP INC is the largest shareholder of the company, while 384.0 institutions own stock in it. As of 2024-06-30, the company held over 25.95 million shares (or 9.7478% of all shares), a total value of $208.12 million in shares.
The next largest institutional holding, with 25.93 million shares, is of PERCEPTIVE ADVISORS LLC’s that is approximately 9.7412% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $207.98 million.
